Skip to main content
. 2017 Mar 28;7:466. doi: 10.1038/s41598-017-00482-4

Figure 3.

Figure 3

CHMFL-BTK-11 ameliorates symptoms in an adjuvant arthritis (AA) rat model. (a–e) The body weight (a), arthritis global assessment (b), arthritis index (c), swollen joint count (d), and paw swelling of rat (e) of AA rats. S.D. rats were intradermal injected with 0.1 ml 10 mg/ml complete Freund’s adjuvant (CFA) into the right rear foot plantar to develop AA rat model. saline injection set as normal control. Drug administration by i.p. injection daily begin at day 17, including DMSO (vehicle AA control), 12.5 mg/kg/d CHMFL-BTK-11, 25.0 mg/kg/d CHMFL-BTK-12, 25.0 mg/kg/d PCI-32765, and 0.5 mg/kg/d MTX. (f) Histology of ankle joint from AA rats. Data shows HE staining and quantification. (Original magnification 100×). (g) Serum OPG and RANKL measurement from AA rats after drug administration. Student’s t-test was used and data were representative of at least 2 independent experiments. ns, P > 0.05,*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.